About Alpha-galactosidase A
Alpha-galactosidase A (GLA) is a protein
from Homo sapiens identified by UniProt accession
P06280, 429 residues long.
MolForge cross-references it against 0 known binders and
354 disease associations.
Target properties
| Protein name | Alpha-galactosidase A |
| UniProt accession | P06280 |
| Gene | GLA |
| Organism | Homo sapiens |
| Length | 429 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (354)
Diseases linked to this target (Open Targets).
- Fabry disease · score 0.90
- cardiomyopathy · score 0.61
- Angiokeratoma corporis diffusum · score 0.58
- Abnormality of the cardiovascular system · score 0.55
- response to deoxygalactonojirimycin · score 0.54
- hypertrophic cardiomyopathy · score 0.54
- Renal insufficiency · score 0.53
- kidney failure · score 0.46
- familial hypertrophic cardiomyopathy · score 0.46
- stroke · score 0.40
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P06280-F1 | alphafold | PREDICTED | 94.31 | — |
Amino-acid sequence (429 residues)
MQLRNPELHL GCALALRFLA LVSWDIPGAR ALDNGLARTP TMGWLHWERF MCNLDCQEEP DSCISEKLFM EMAELMVSEG WKDAGYEYLC IDDCWMAPQR DSEGRLQADP QRFPHGIRQL ANYVHSKGLK LGIYADVGNK TCAGFPGSFG YYDIDAQTFA DWGVDLLKFD GCYCDSLENL ADGYKHMSLA LNRTGRSIVY SCEWPLYMWP FQKPNYTEIR QYCNHWRNFA DIDDSWKSIK SILDWTSFNQ ERIVDVAGPG GWNDPDMLVI GNFGLSWNQQ VTQMALWAIM AAPLFMSNDL RHISPQAKAL LQDKDVIAIN QDPLGKQGYQ LRQGDNFEVW ERPLSGLAWA VAMINRQEIG GPRSYTIAVA SLGKGVACNP ACFITQLLPV KRKLGFYEWT SRLRSHINPT GTVLLQLENT MQMSLKDLL
Explore Alpha-galactosidase A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets